0.8859
Schlusskurs vom Vortag:
$0.9019
Offen:
$0.8905
24-Stunden-Volumen:
69,734
Relative Volume:
0.40
Marktkapitalisierung:
$38.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-0.4977
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
-0.03%
1M Leistung:
-1.67%
6M Leistung:
-15.63%
1J Leistung:
-77.11%
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Vergleichen Sie PRLD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PRLD
Prelude Therapeutics Inc
|
0.8859 | 50.04M | 0 | -131.52M | -107.56M | -1.78 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-07-29 | Eingeleitet | Jefferies | Buy |
2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
2021-03-09 | Eingeleitet | Barclays | Overweight |
2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
2020-10-20 | Eingeleitet | BofA Securities | Buy |
2020-10-20 | Eingeleitet | Goldman | Neutral |
2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges By Investing.com - Investing.com South Africa
Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges - Investing.com
Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal - insights.citeline.com
AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MyChesCo
Mineralys Therapeutics to Present at Bank of America Health Care Conference - MyChesCo
Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs - MyChesCo
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter
What is HC Wainwright’s Estimate for PRLD Q2 Earnings? - Defense World
SEED Therapeutics Unveils Groundbreaking Advances in Cancer Research at AACR 2025 - MyChesCo
Q1 Earnings Forecast for PRLD Issued By HC Wainwright - Defense World
Prelude Therapeutics Reports Q1 2025 Financial Results - TipRanks
JPMorgan Chase & Co. Purchases 55,183 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics (NASDAQ:PRLD) Given Buy Rating at HC Wainwright - Defense World
Prelude Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Prelude Therapeutics (PRLD) Rating Reiterated with $5 Target by HC Wainwright | PRLD Stock News - GuruFocus
Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025 - MyChesCo
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MyChesCo
Prelude Therapeutics Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Increases Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics to Participate in Citizens Life Sciences Conference - Bluefield Daily Telegraph
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo
JMP Securities Reaffirms Market Outperform Rating for Prelude Therapeutics (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies - MSN
JMP maintains $4 target on Prelude Therapeutics stock By Investing.com - Investing.com Canada
Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MyChesCo
Prelude Announces Presentations at 2025 AACR Annual Meeting | PR - GuruFocus
Prelude Therapeutics Presents Preclinical Data on First-in-Class SMARCA2 and Selective KAT6A Degraders at AACR Annual Meeting - Nasdaq
Prelude Announces Presentations at 2025 AACR Annual Meeting - Yahoo Finance
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MyChesCo
Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo
HC Wainwright Issues Positive Forecast for PRLD Earnings - Defense World
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know - MSN
PRLD stock touches 52-week low at $0.61 amid market challenges - Investing.com
Charles Schwab Investment Management Inc. Sells 16,049 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Palvella Therapeutics Reports 2024 Financial Results and Advances Rare Disease Pipeline - MyChesCo
Prelude Therapeutics reports preclinical profile of first-in-human SMARCA2 degrader - BioWorld MedTech
Prelude Therapeutics Founder Acquires 28% More Stock - Yahoo
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Prelude Therapeutics stock surges on insider buying By Investing.com - Investing.com South Africa
Prelude Therapeutics stock surges on insider buying - Investing.com
Prelude Therapeutics chief chemistry officer acquires $69,250 in stock By Investing.com - Investing.com South Africa
Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock - Investing.com Australia
Prelude Therapeutics chief chemistry officer acquires $69,250 in stock - Investing.com
Prelude Therapeutics CEO Vaddi Krishna acquires $467,437 in stock By Investing.com - Investing.com South Africa
PRLD stock touches 52-week low at $0.66 amid sharp annual decline - Investing.com
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):